Estimated Medical Expenditure and Risk of Job Loss among Rheumatoid Arthritis Patients undergoing Tofacitinib Treatment: Post Hoc Analyses of Two Randomized Clinical Trials
Rheumatology doi: 10.1093/rheumatology/kex087
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Rheumatology doi: 10.1093/rheumatology/kex087
Rheumatology. Doi 10.1093/rheumatology/kex068
N Engl J Med. 2017 May 4;376(18):1723-1736. DOI 10.1056/NEJMoa1606910
Tofacitinib, at a dose of 10 mg twice daily, was more effective than placebo for induction of remission and mucosal healing in patients with moderately to severely active ulcerative colitis. Furthermore, maintenance therapy with tofacitinib, at a dose of either 5 mg or 10 mg twice daily, was more effective than placebo in sustaining remission and mucosal healing.
Ann Rheum Dis Published Online First: 06March2017. doi:10.1136/annrheumdis-2016-210715
Nature Reviews Rheumatology 2017;13:234–43
Arthritis Rheumatol 2017 Feb 28. doi: 10.1002/art.40084
Clin Exp Rheumatol 2017 Jan 4
Rheumatology 2017;56:46–57.
J Manag Care Spec Pharm. 2016 Dec;22(12):1457-1471.
Clin Ther 2016;38:2628–40.